[A Descriptive Overview of Cases of Congenital Cytomegalovirus at a Tertiary Hospital Between 2017 and 2023]

Overview

Journal Rev Esp Quimioter

Specialty Pharmacology

Date 2024 May 23

PMID 38779888

Authors

E Medina Garcia

A Berzosa

M Illan Ramos

V Cursach Pedrosa

C Aranda Cazon

G Herranz Carrillo

E Criado Vega

J T Ramos Amador

Affiliations

Soon will be listed here.

Abstract

Objective: Cytomegalovirus infection (CMV) is the most common congenital infection in developed countries. The aim of our study was to describe the features of the children that have congenital CMV infection at our hospital for the last 6 years.

Methods: A retrospective descriptive study was designed that included all the children with CMV congenital infection that were diagnosed at tertiary hospital of Madrid Community between 2017 and 2023.

Results: Twenty-two children were included. 54.5% have a prenatal diagnosis, 50% of them were in the third trimester, 25% at first trimester and 25% at the second. 22.7% were preterm. CMV was isolated in all the samples with CV more than 1000 copies/ml. When CMV was made in blood, 11/22 (50%) had a high CV. Only one newborn had a high CV at CRL. 44% have affectation at transfontanellar ultrasound evidenced by vasculopathy (62%), intraventricular hemorrhage (IVH) or periventricular calcifications (20%). 68% were asymptomatic, al though 20% had a retarded intrauterine growth (RIG) at birth or clinical features or analytical were objectified (neutropenia, thrombocytopenia, cholestasis). 33% got treatment with val ganciclovir and 33% had sequelae (hearing loss).

Conclusions: CMV congenital infection is still a severe public health issue in developed countries. Most of the cases are mild or asymptomatic even though we should have high clinical suspicion with compatible symptoms and consistent maternal history in order to make an early diagnosis and treatment to prevent or reduce sequelae.

References

Kimberlin D, Jester P, Sanchez P, Ahmed A, Arav-Boger R, Michaels M . Valganciclovir for symptomatic congenital cytomegalovirus disease. N Engl J Med. 2015; 372(10):933-43. PMC: 4401811. DOI: 10.1056/NEJMoa1404599. View

Blazquez-Gamero D, Soriano-Ramos M, Vicente M, Pallas-Alonso C, Perez-Rivilla A, Garcia-Alvarez M . Prevalence and Clinical Manifestations of Congenital Cytomegalovirus Infection in a Screening Program in Madrid (PICCSA Study). Pediatr Infect Dis J. 2020; 39(11):1050-1056. DOI: 10.1097/INF.0000000000002808. View

Gantt S, Bitnun A, Renaud C, Kakkar F, Vaudry W . Diagnosis and management of infants with congenital cytomegalovirus infection. Paediatr Child Health. 2018; 22(2):72-74. PMC: 5804742. DOI: 10.1093/pch/pxx002. View

Leruez-Ville M, Ghout I, Bussieres L, Stirnemann J, Magny J, Couderc S . In utero treatment of congenital cytomegalovirus infection with valacyclovir in a multicenter, open-label, phase II study. Am J Obstet Gynecol. 2016; 215(4):462.e1-462.e10. DOI: 10.1016/j.ajog.2016.04.003. View

Lazzarotto T, Blazquez-Gamero D, Delforge M, Foulon I, Luck S, Modrow S . Congenital Cytomegalovirus Infection: A Narrative Review of the Issues in Screening and Management From a Panel of European Experts. Front Pediatr. 2020; 8:13. PMC: 7006044. DOI: 10.3389/fped.2020.00013. View

Nicloux M, Peterman L, Parodi M, Magny J . Outcome and management of newborns with congenital cytomegalovirus infection. Arch Pediatr. 2020; 27(3):160-165. DOI: 10.1016/j.arcped.2020.01.006. View

Gomes A, Baraniak I, Lankina A, Moulder Z, Holenya P, Atkinson C . The cytomegalovirus gB/MF59 vaccine candidate induces antibodies against an antigenic domain controlling cell-to-cell spread. Nat Commun. 2023; 14(1):1041. PMC: 9950427. DOI: 10.1038/s41467-023-36683-x. View

Goycochea-Valdivia W, Baquero-Artigao F, Del Rosal T, Frick M, Rojo P, Echeverria M . Cytomegalovirus DNA Detection by Polymerase Chain Reaction in Cerebrospinal Fluid of Infants With Congenital Infection: Associations With Clinical Evaluation at Birth and Implications for Follow-up. Clin Infect Dis. 2017; 64(10):1335-1342. DOI: 10.1093/cid/cix105. View

Ssentongo P, Hehnly C, Birungi P, Roach M, Spady J, Fronterre C . Congenital Cytomegalovirus Infection Burden and Epidemiologic Risk Factors in Countries With Universal Screening: A Systematic Review and Meta-analysis. JAMA Netw Open. 2021; 4(8):e2120736. PMC: 8383138. DOI: 10.1001/jamanetworkopen.2021.20736. View

10.

Baquero-Artigao F . [Consensus document from the Spanish Society of Paediatric Infectious Diseases (SEIP) on the diagnosis and treatment of congenital cytomegalovirus infection]. An Pediatr (Barc). 2009; 71(6):535-47. DOI: 10.1016/j.anpedi.2009.07.029. View

11.

de la Calle M, Baquero-Artigao F, Rodriguez-Molino P, Cabanes M, Cabrera M, Antolin E . Combined treatment with immunoglobulin and valaciclovir in pregnant women with cytomegalovirus infection and high risk of symptomatic fetal disease. J Matern Fetal Neonatal Med. 2020; 35(16):3196-3200. DOI: 10.1080/14767058.2020.1815188. View

12.

Luck S, Wieringa J, Blazquez-Gamero D, Henneke P, Schuster K, Butler K . Congenital Cytomegalovirus: A European Expert Consensus Statement on Diagnosis and Management. Pediatr Infect Dis J. 2017; 36(12):1205-1213. DOI: 10.1097/INF.0000000000001763. View

13.

Revello M, Lazzarotto T, Guerra B, Spinillo A, Ferrazzi E, Kustermann A . A randomized trial of hyperimmune globulin to prevent congenital cytomegalovirus. N Engl J Med. 2014; 370(14):1316-26. DOI: 10.1056/NEJMoa1310214. View

14.

Nigro G, Adler S, La Torre R, Best A . Passive immunization during pregnancy for congenital cytomegalovirus infection. N Engl J Med. 2005; 353(13):1350-62. DOI: 10.1056/NEJMoa043337. View